Rivoglitazone

From Wikipedia, the free encyclopedia

This is an old revision of this page, as edited by Wknight94 (talk | contribs) at 01:07, 9 September 2008 (Reverted edits by 141.155.36.231 (talk) to last version by ChemNerd). The present address (URL) is a permanent link to this revision, which may differ significantly from the current revision.

Rivoglitazone
Identifiers
  • 5-{4-[(6-methoxy-1-methyl-1H-benzimidazol-2-yl) methoxy]benzyl}-1,3-thiazolidine-2,4-dione
CAS Number
PubChem CID
Chemical and physical data
FormulaC20H19N3O4S
Molar mass397.448 g/mol g·mol−1
3D model (JSmol)
  • CN1C2=C(C=CC(=C2)OC)N=C1COC3=CC=C(C=C3)CC4C(=O)NC(=O)S4

Rivoglitazone (INN) is a thiazolidinedione undergoing research for use in the treatment of type 2 diabetes.[1]

It is being developed by Daiichi Sankyo Co.

References

  1. ^ Schimke K, Davis TM (2007). "Drug evaluation: rivoglitazone, a new oral therapy for the treatment of type 2 diabetes". Curr Opin Investig Drugs. 8 (4): 338–44. PMID 17458185.


Stub icon

This pharmacology-related article is a stub. You can help Wikipedia by expanding it.

Retrieved from "https://en.wikipedia.org/w/index.php?title=Rivoglitazone&oldid=237184606"